Apitoria Pharma gets Form 483 with 10 observations from USFDA

The observations are of procedural in nature and will be responded to within the stipulated time

Briefs: Biocon, Aarti Drugs and Glenmark Pharmaceuticals

Glenmark Pharmaceuticals Limited has informed that the USFDA has issued Form 483 with zero observations

Briefs: Fermenta Biotech and Family Care Hospitals

Fermenta Biotech’s API manufacturing facility receives EU GMP compliance certificate

Briefs: Ami Organics and Dr. Reddy’s Laboratories

Ami informs that PMDA Japan has issued Inspection Result Report declaring the Sachin facility as a Good Manufacturing Practices (GMP) compliant.

Supriya Lifescience reports robust Q1 FY25 results with 21.7% revenue growth

European markets now contribute 51% of our business revenue up from 43% in Q4 FY24 and 34% in Q1 FY24

Aarti Drugs posts Q1 FY25 PAT lower at Rs. 33.3 Cr

Rusan Pharma’s API plant in Ankleshwar receives USFDA GMP approval

Rusan’s API facility in Ankleshwar is GMP approved by other stringent international agencies as well

Briefs: Family Care Hospitals, Laurus Labs and Bafna Pharmaceuticals

Laurus Labs receives EIR from USFDA for API facilities

Briefs: Dr. Reddy's Laboratories and Ami Organics

Dr. Reddy's Laboratories gets Form 483 from USFDA with 4 observations for API facility

Supriya Lifescience FY24 PAT up 32%

The Profit After Tax (PAT) for Q4 FY24 at Rs 36.40 crore, compared to Rs 38.23 crore in Q4 FY23